Page 152 - Read Online

Page 14 of 15 Zacharakis et al. Hepatoma Res 2018;4:65 I http://dx.doi.org/10.20517/2394-5079.2018.76

87. Xu H, Dong X, Chen Y, Wang X. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin Chem Lab Med
2018;56:479-84.
88. Zhang J, Zhang D, Zhao Q, Qi J, Li X, et al. A distinctively expressed long noncoding RNA, RP11-466I1.1, may serve as a prognostic
biomarker in hepatocellular carcinoma. Cancer Med 2018; doi: 10.1002/cam4.1565.
89. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. Risk factors contributing to early and late phase intrahepatic recurrence
of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.
90. Xu W, Cao L, Chen L, Li J, Zhang XF, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell
separation strategy. Clin Cancer Res 2011;17:3783-93.
91. Fan JL, Yang YF, Yuan CH, Chen H, Wang FB. Circulating tumor cells for predicting the prognostic of patients with hepatocellular
carcinoma: a meta analysis. Cell Physiol Biochem 2015;37:629-40.
92. Sun C, Liao W, Deng Z, Li E, Feng Q, et al. The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: a meta-
analysis. Medicine (Baltimore) 2017; doi: 10.1097/MD.0000000000007513.
93. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-
50.
94. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free dna, a novel procoagulant stimulus. J
Thromb Haemost 2011;9:2313-21.
95. García-Olmo DC, Domínguez C, García-Arranz M, Anker P, Stroun M, et al. Cell-free nucleic acids circulating in the plasma of colorectal
cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res 2010;70:560-7.
96. Kirk GD, Lesi OA, Mendy M, Szymañska K, Whittle H, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk
of hepatocellular carcinoma. Oncogene 2005;24:5858-67.
97. Liao W, Mao Y, Ge P, Yang H, Xu H, et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for
hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2015; doi: 10.1097/md.0000000000000722.
98. Shi M, Chen MS, Sekar K, Tan CK, Ooi LL, et al. A blood-based three-gene signature for the non-invasive detection of early human
hepatocellular carcinoma. Eur J Cancer 2014;50:928-36.
99. Hann HW, Jain S, Park G, Steffen JD, Song W, et al. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.
Hepatoma Res 2017;3:105-11.
100. Luo P, Yin P, Hua R, Tan Y, Li Z, et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of
hepatocellular carcinoma. Hepatology 2017; doi: 10.1002/hep.29561.
101. Yin H, Tan Z, Wu J, Zhu J, Shedden KA, et al. Mass-selected site-specific core-fucosylation of serum proteins in hepatocellular carcinoma.
J Proteome Res 2015;14:4876-84.
102 Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, et al. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis
and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 2009;9:271.
103. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver
disease. Clin Cancer Res 2008;14:470-7.
104. Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol 2012;57:663-74.
105. Walker AJ, Peacock CJ, Pedergnana V; STOP-HCV Consortium, Irving WL. Host genetic factors associated with hepatocellular carcinoma
in patients with hepatitis C virus infection: a systematic review. J Viral Hepat 2018;25:442-56.
106. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, et al. Prognostic gene-expression signature for patients with hepatitis C-related
early-stage cirrhosis. Gastroenterology 2013;144:1024-30.
107. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
108. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, et al. A molecular signature to discriminate dysplastic nodules from early
hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-67.
109. Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteomics Bioinformatics 2017;15:59-72.
110. Cabel L, Proudhon C, Buecher B, Pierga JY, Bidard FC. Circulating tumor DNA detection in hepatocellular carcinoma. Ann Oncol
2018;29:1094-6.
111. Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, et al. A hepatocellular carcinoma 5-gene score associated with survival of
patients after liver resection. Gastroenterology 2013;145:176-87.
112. Villa E, Critelli R, Lei B, Marzocchi G, Cammà C, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular
carcinomas and worst survival. Results from a prospective study. Gut 2016;65:861-9.
113. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
N Engl J Med 2008;359:1995-2004.
114. Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to
sorafenib in hepatocellular carcinoma. Hepatology 2013;57:1407-15.
115. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, et al. Prognostic factors and predictors of sorafenib benefit in patients with
hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017;67:999-1008.
116. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat
Rev Clin Oncol 2015;12:408-24.
117. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, et al. Plasma biomarkers as predictors of outcome in patients with advanced
hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
118. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib
treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
119. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.